Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM

Core Insights - Bionano Genomics has announced a study that presents a new method for analyzing multiple myeloma (MM) using optical genome mapping (OGM), which addresses challenges in traditional cytogenetic methods [1][3] - The study indicates that the new OGM method can reduce the required number of CD138-positive cells for analysis by half, making it easier to analyze limited samples [1][3] - OGM has shown a 93% concordance rate with the current standard method, FISH, while also identifying over 22 additional genetic variants not detected by FISH [6] Company Overview - Bionano Genomics specializes in genome analysis solutions aimed at transforming genomic research and diagnostics through OGM technology [4] - The company provides OGM solutions for various research applications and offers diagnostic testing services through its subsidiary, Lineagen, Inc. [4] - Bionano's mission is to enhance the understanding of the genome, which is critical for addressing complex biological and medical questions [4]